… This study seeks to obtain data which will help explore the optimal sequence of LT for
symptomatic BM … Based on the inclusion criteria, a total of 87 patients were included in this study. …

… erlotinib in the control arm (Arm A) in the current study. We intend to explore the clinical
benefit of sequential pemetrexed and erlotinib … the extended study of single agent erlotinib. We …

… this study have potential to decrease erlotinib serum … studied patients with detected erlotinib
interactions, we found that a third of them had one PPI, pantoprazole. Interaction of erlotinib …

… this study received chemotherapy followed by erlotinib, whereas most other studies evaluated
… There was a limited number of comparative studies investigating the efficacy and safety of …

… In the present study erlotinib-loaded gellan gum beads were prepared. The SEM image of
the beads revealed a spherical shape. The functional groups of beads were identified using …

… Additional networks were created for the sensitivity analyses (erlotinib and gefitinib as separate
nodes with erlotinib defined as the reference treatment). Networks for subgroup analyses …

… the best drug candidate from Erlotinib, a renowned anti-cancer agent, derivatives. A total
of 200 structures were selected for the 2D crystal structure of erlotinib based on molecular …

… study, we aimed to develop a therapy against erlotinib resistance. We observed that HDAC6
is overexpressed in erlotinib… is responsible for erlotinib resistance in pancreatic cancer cells. …

… PKA-independent pathway activated by erlotinib, and that the phosphoinositide dependent
… for erlotinib-induced AQP2 activation. Using our LLC-AQP2 cell model, we show that erlotinib-…

… Aim: This study aimed to formulate erlotinib hydrochloride (ERT-HCL)-loaded chitosan (CS)
and poly (lactic-co-glycolic acid) (PLGA) nanoparticles (NPs) using Quality-by-Design (QbD) …